Where Angels Fear To Tread: Lessening The Perils Of CRISPR-Based Therapies
Executive Summary
CRISPR is in the headlines once again, but for all the wrong reasons. While germline gene editing remains taboo in legitimate research, it is a reminder that there is much to be learned in ensuring the safety of the technique in general. AstraZeneca has developed a new method which it believes will help avoid off-target effects, an executive explains to In Vivo.
You may also be interested in...
Editas' EDIT-101 Set To Be First In Vivo CRISPR Gene-Editing Therapy In Clinic
Editas CEO says recent IND filing to treat LCA10 eye disease puts EDIT-101 on track to be first CRISPR medicine administered directly to patients. Bosley also voices relief at recent US IP court ruling.
CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?
CRISPR Therapeutics and Vertex initiated the first human study of CRISPR gene-editing technology with an industry sponsor, following an investigator-sponsored study initiated in China two years ago. These are not the first gene-editing trials, but they're important milestones for the CRISPR field.
AstraZeneca deals take CRISPR to its drug discovery heart
AstraZeneca has leveraged its "open-innovation" approach to strike four deals in the ground-breaking CRISPR genome editing field, positioning it well against its pharma peers.